KOBE, Japan--(BUSINESS WIRE)--M’s Science Corporation (MSC), a clinical stage discovery and development company announced today that it initiated a Phase 2 study in Europe with its lead product SA4503 for treatment of stroke. Earlier this year, MSC announced the initiation of a Phase 2 trial with SA4503 for the treatment of major depression.
